Regeneron Pharms (NASDAQ:REGN) Reaching An Inflection Point; Wells Fargo Coverage Initiated as “Outperform”


How Wells Fargo Currently Rates Regeneron Pharms (NASDAQ:REGN)

Wells Fargo issued “Outperform” rating on Regeneron Pharms (NASDAQ:REGN). The firm launched coverage on shares of REGN in a very recent research note announced on Friday morning.

From a total of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock, 12 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 57% of the ratings are positive. The highest target price is $700 while the lowest target price is $543. The mean of all analyst targets is $625.84 with a 10.07% above today’s ($547.85) stock price. Regeneron Pharmaceuticals Inc. was the topic of 23 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. RBC Capital Markets maintained shares on November 5 with “Outperform” rating. Vetr upgraded shares to “Buy” rating and $618.66 target share price in a report from an August 21. UBS upgraded REGN stock in a recent report from September 7 to “Buy” rating. Zacks upgraded the rating on August 11. Zacks has a “Hold” rating and a $668 price target on shares. Finally, Chardan Capital Markets downgraded the stock to “Neutral” rating in a report issued on an August 31.

Approximately 158,236 shares of stock traded hands. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 13.70% since May 1, 2015 and is uptrending. It has outperformed by 16.49% the S&P500.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $56.09 billion. The Firm commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis , asthma and atopic dermatitis. It has 106.72 P/E ratio. The Company’s marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use.

According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)” Get a free copy of the Zacks research report on Regeneron Pharmaceuticals Inc (REGN).